$1.28 Billion is the total value of Slate Path Capital LP's 13 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 110.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GDX | New | VANECK VECTORS ETF TRgold miners etf | $249,113,000 | – | 8,990,000 | +100.0% | 19.48% | – |
| PYPL | Buy | PAYPAL HLDGS INC | $214,679,000 | +4.1% | 5,880,000 | +10.0% | 16.79% | +4.8% |
| CHTR | New | CHARTER COMMUNICATIONS INC Ncl a | $171,480,000 | – | 750,000 | +100.0% | 13.41% | – |
| TRIP | Buy | TRIPADVISOR INC | $120,563,000 | +15.1% | 1,875,000 | +19.0% | 9.43% | +16.0% |
| SYMC | New | SYMANTEC CORP | $113,073,000 | – | 5,505,000 | +100.0% | 8.84% | – |
| PODD | INSULET CORP | $82,253,000 | -8.8% | 2,720,000 | 0.0% | 6.43% | -8.1% | |
| TECK | New | TECK RESOURCES LTDcl b | $80,535,000 | – | 6,115,000 | +100.0% | 6.30% | – |
| TSO | TESORO CORP | $74,545,000 | -12.9% | 995,000 | 0.0% | 5.83% | -12.2% | |
| AA | New | ALCOA INC | $65,261,000 | – | 7,040,000 | +100.0% | 5.10% | – |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $62,981,000 | -11.6% | 1,135,000 | 0.0% | 4.93% | -11.0% | |
| OPHT | OPHTHOTECH CORP | $21,943,000 | +20.7% | 430,000 | 0.0% | 1.72% | +21.6% | |
| X | New | UNITED STATES STL CORP NEW | $12,645,000 | – | 750,000 | +100.0% | 0.99% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $9,454,000 | – | 420,000 | +100.0% | 0.74% | – |
| TWC | Exit | TIME WARNER CABLE INC | $0 | – | -110,000 | -100.0% | -1.75% | – |
| CHTR | Exit | CHARTER COMMUNICATIONS INC Dcl a new | $0 | – | -755,000 | -100.0% | -11.87% | – |
| GDX | Exit | MARKET VECTORS ETF TRgold miner etf | $0 | – | -10,390,000 | -100.0% | -16.11% | – |
| SPY | Exit | SPDR S&P 500 ETF TRcall | $0 | – | -1,600,000 | -100.0% | -25.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CHARTER COMMUNICATIONS INC N | 30 | Q3 2023 | 15.2% |
| ALNYLAM PHARMACEUTICALS INC | 30 | Q3 2020 | 8.9% |
| UNITED STATES STL CORP NEW | 24 | Q3 2023 | 11.4% |
| NEW YORK TIMES CO | 23 | Q3 2023 | 10.9% |
| VANECK VECTORS ETF TR | 21 | Q3 2023 | 19.5% |
| PAN AMERN SILVER CORP | 21 | Q3 2023 | 7.6% |
| CUE BIOPHARMA INC | 17 | Q3 2023 | 1.3% |
| BARRICK GOLD CORPORATION | 16 | Q4 2020 | 15.7% |
| MOSAIC CO NEW | 15 | Q4 2021 | 16.8% |
| MEDICINES CO | 15 | Q4 2019 | 12.2% |
View Slate Path Capital LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cue Biopharma, Inc. | February 14, 2023 | 2,402,455 | 5.6% |
| Stitch Fix, Inc. | February 14, 2023 | ? | ? |
| Cyclerion Therapeutics, Inc. | January 13, 2023 | 7,157,601 | 16.5% |
| Zimmer Energy Transition Acquisition Corp. | February 14, 2022 | 2,000,000 | 5.8% |
| 5:01 Acquisition Corp. | February 11, 2022 | 500,000 | 5.8% |
| Hippo Holdings Inc. | February 11, 2022 | 350,000 | 0.1% |
| Warner Music Group Corp. | February 11, 2022 | 3,134,779 | 2.6% |
| Reinvent Technology Partners Z | February 16, 2021 | 1,750,000 | 7.6% |
View Slate Path Capital LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-22 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-13 |
| SC 13G | 2022-11-18 |
View Slate Path Capital LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.